Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.
Voriconazole is the treatment of choice for invasive aspergillosis and its use is increasing in pediatrics. Minimal pharmacokinetic data exist in young children. We report voriconazole concentrations for 10 children <3 years of age and pharmacokinetic parameters for 1 infant who had therapeutic drug monitoring performed. Trough concentrations were unpredictable based on dose, highlighting the need to follow values during therapy.
Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Elizabeth H
EH
Doby
Daniel K
DK
Benjamin
Anne J
AJ
Blaschke
Robert M
RM
Ward
Andrew T
AT
Pavia
Paul L
PL
Martin
Timothy A
TA
Driscoll
Michael
M
Cohen-Wolkowiez
Cassandra
C
Moran
D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002675:Child, Preschool; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D007223:Infant; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy*; D008297:Male; D010949:Plasma / Q000737:chemistry; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014230:Triazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole